 Norwood, MA, June 01, 2021 GLOBE NEWSWIRE -- Corbus Pharmaceuticals Holdings, Inc. NASDAQ: CRBP Corbus or the Company, today announced licensing deals for two new monoclonal antibodies mAbs, CRB-601 and CRB-602, that target integrins to inhibit activation of transforming growth factor β TGFβ. This new integrin program, in addition to the existing endocannabinoid system program, strengthens and diversifies Corbus immunology pipeline for inflammatory, fibrotic, and metabolic diseases, and cancer. With these additions, Corbus expects to have four compounds other than lenabasum in Phase 1 testing in 2022. 